Genizon BioSciences Inc. Collaborating with NDEI to Enhance Gene Discovery Findings in Schizophrenia
11/6/2007 11:10:32 AM
MONTREAL--(BUSINESS WIRE)--Genizon BioSciences Inc. and Neuropsychiatrie, Découverte & Innovation Inc. (NDEI) today announced an agreement under which the groups will collaborate to enhance and potentially add to discoveries made by Genizon early this year in a genome-wide association study of schizophrenia. Genizon’s study identified multiple genes associated with the disease using DNA samples from patients from the Quebec Founder Population.
Schizophrenia is a chronic, severe and disabling disease of the central nervous system affecting between 0.5 percent and 1 percent of the adult population worldwide. The causes involve both genetic and environmental factors. Treatment generally involves the use of antipsychotic medication which is effective in treating some disease symptoms, but can also produce significant side effects.
comments powered by